INTRODUCTION
In spite of advances in cardiopulmonary bypass with various cardioprotective techniques, significant morbidity and mortality remain following open heart surgery in children. [1] Heart-type fatty acid-binding protein (H-FABP) is a small cytoplasmic protein (15 kDa) released from cardiac myocytes following myocardial injury. [2, 3] H-FABP is a very early marker of myocardial injury, reaching its peak release within 1 h in adult myocardial infarct patients. We evaluated the potential of H-FABP as a predictor of clinical outcome in children undergoing cardiac surgery, as compared with the more slowly released cardiac injury markers (creatine kinase-myocardial band [CK-MB] and troponin-I, both peaking 3-6 h after injury) and as compared with total bypass time.
METHODS
This is a retrospective study of laboratory and patient file data from a blinded randomized, controlled trial (RCT) that was performed at Narayana Institute of Cardiac Sciences, Bengaluru, India, in accordance with the Helsinki Declaration. It was
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: There was a strong correlation between the three injury markers. For all three injury markers, there was a very strong correlation between the peak value and the respective AUC (correlation coefficients between peak and AUC for CK-MB 0.99, troponin-I 0.99, H-FABP 0.97). Table 1 and Figure 1 contain detailed results.
DISCUSSION
Postoperative cardiac biomarker release can be attributed to ischemia and reperfusion injury, but also to manipulation and direct myocardial injury during surgery. In accordance with previous reports, [2] H-FABP showed an early rise and peak after the time of injury, i.e., following ACC release. Despite its different release pattern, H-FABP had a strong correlation with the other cardiac biomarkers CK-MB and troponin-I, which peaked at 3 h after ACC release in almost all patients.
The observed negative correlation between age and cardiac biomarker release may be due to the higher sensitivity of younger myocardium to ischemia-reperfusion injury, [5] or approved by the Institutional Ethical Committees and registered (CTRI/2014/03/004468). [4] Children 1-16 years undergoing surgical ventricular septal defect closure were included in an RCT with sildenafil preconditioning aiming to reduce ischemia/reperfusion injury. [4] As no significant differences between sildenafil and placebo were found, all patients were pooled together for the current analysis. Serum CK-MB, troponin-I, and H-FABP were measured at baseline and at 1, 3, and 6 h after aortic declamping. CK-MB and troponin-I were assessed by chemiluminescence immunoassay (Siemens Healthcare Diagnostics, East Walpole, USA). H-FABP samples were centrifuged and stored at −20°C, to be measured in an external laboratory after the study using immunoturbidimetry (Randox Laboratories Limited, County Antrim, United Kingdom). Per-and post-operative measurements of aortic cross-clamp (ACC) time, bypass time, ventilation-weaning time, inotropy time, and Intensive Care Unit (ICU) stay were noted. Echocardiographic left ventricular ejection fraction (LVEF) was assessed 5-7 days after surgery, before discharge. The area under the curve (AUC) was calculated for the injury marker release using a trapezoidal method. [4] We calculated Spearman's rank correlations (rho) because of small sample size, nonnormal data distribution, and unknown relationship nature between the parameters. We considered correlation coefficients as follows: 0-0. 
RESULTS
Of 39 patients participating in the RCT, [4] seven were excluded for missing sample (s). The remaining patients' data were expressed as median (interquartile range due to the fact that operations on small hearts may require somewhat longer bypass times and more manipulation.
One previous pediatric study by Hasegawa et al . has compared the injury markers H-FABP, CK-MB, and troponin-T and their correlation with postoperative outcome. [6] The Hasegawa et al. article found similar good correlations between the injury markers but differed with our study by finding a correlation between H-FABP release and postoperative outcome (especially increased inotropic needs). [6] This is probably accounted for by the fact that the Hasegawa et al. study [6] included more complex operations (including double outlet right ventricle, Tetralogy of Fallot, valvular disease, and atrioventricular septum defects) and had considerably longer cross-clamp times (mean 77 min) and cardiopulmonary bypass times (mean 146 min) than our study. Furthermore, the larger number of studied patients by Hasegawa (n = 100) may have enabled them to detect differences that were not revealed in our smaller study.
Limitations
The small sample size and short bypass times in relatively simple cardiac surgery demand caution in extrapolating conclusions to complex, longer operations. Given the limitations of this study, research including a larger sample of longer, more complex operations may serve to more definitively provide guidance on the usefulness of H-FABP in care for pediatric patients after cardiac surgery.
CONCLUSION
H-FABP was not proven to be a clinically useful predictor of clinical outcomes in pediatric cardiac surgery in this study. H-FABP shows similarly poor-moderate correlations with clinical outcomes compared with CK-MB, troponin-I, and cardiopulmonary bypass time. Therefore, we consider that it is not justified to perform repeated, invasive, and costly additional testing in clinical practice.
